Wayne Goodman, MD
- PROFESSOR AND SYSTEM CHAIR | Psychiatry
- PROFESSOR | Neuroscience
On July 1, 2009, Dr. Goodman was appointed Professor and Chairman of the Department of Psychiatry at the Mount Sinai School of Medicine in New York City. He is the Esther and Joseph Klingenstein Professor of Psychiatry and Professor in the Department of Neuroscience.
Prior to joining Mt. Sinai, he served as Director, Division of Adult Translational Research and Treatment Development (DATR), at the National Institute of Mental Health in Bethesda, Maryland from 2007-2009. He has conducted pioneering research in the field of Obsessive-Compulsive Disorder (OCD) and is the principal developer of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the gold standard for assessing OCD. He is co-founder of the Obsessive Compulsive Foundation, the national patient advocacy organization for this disorder.
Dr. Goodman is a native of New York City and attended the Bronx High School of Science. A graduate of Columbia University with a BS in electrical engineering, Dr. Goodman received his medical degree from Boston University and completed his internship, residency, and a research fellowship at Yale University School of Medicine where he remained on faculty until 1993 as an Associate Professor. In 1994, he joined the University of Florida in Gainesville where he served as Chairman of the Department of Psychiatry for nine years. Dr. Goodman has published more than 250 articles in scientific journals and has been principal investigator on NIMH-funded grants since 1992. He is a member of the American College of Neuropsychopharmacology and a Distinguished Fellow of the American Psychiatric Association. He is the 2010 recipient of the Mysell Lecture Award from Harvard University and in 2012 he received the Lifetime Career Achievement Award from International OCD Foundation.
As Chair of Psychiatry, Dr. Goodman works closely with the new Mount Sinai Brain Institute to conduct research on neuropsychiatric disorders such as schizophrenia, Alzheimer's disease, and mood disorders. Dr. Goodman is an expert psycho-pharmacologist who previously served as Chair of the Food and Drug Administration's (FDA's) Psychopharmacologic Drug Advisory Committee.
Optimizing Care Today and Developing the Treatments of Tomorrow at Mount Sinai
In the News
Dr. Goodman discusses OCD in The Daily News feature The Daily Check Up.
View the PDF.
Financial & Billing Information
Please direct any detailed billing or financial inquires to the Mount Sinai Psychiatry billing customer service number at 212-659-8752.
Psychiatry, American Board of Psychiatry and Neurology
- Obsessive-Compulsive Disorder
- Tourette Syndrome
MD, Boston University
Internship, Transitional, Hospital of St. Raphael
Residency, Psychiatry, Yale-New Haven Psychiatric Hospital
Fellowship, , Yale School of Medicine
My primary areas of research interest are obsessive compulsive disorder (OCD) and related disorders such as Tourette's Syndrome (TS) in children and adults. I am interested in advancing the treatment of OCD through a better understanding of its pathophysiology. During a span of 20 years, I have investigated the phenomenology, neurobiology and treatment of OCD. In recent years, I have focused on developing approaches to treatment-resistant OCD including the study of Deep Brain Stimulation (DBS).
- A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (DTMS) for the treatment of Obsessive Compulsive Disorder
The purpose of this study is to see if deep repetitive transcranial magnetic stimulation (DTMS) is effective in treating subjects suffering from Obsessive Compulsive Disorder (OCD) who are treated with SSRI medications.
To qualify for this study, patients must:...
- A Clinical Pilot Study Examining Bilateral Inhibition of the Lateral Habenula as a Target for Deep Brain Stimulation in Intractable Depression
The Departments of Psychiatry and Neurosurgery at the Icahn School of Medicine at Mount Sinai are currently seeking participants with treatment-resistant depression (TRD) for research assessing the safety and preliminary efficacy of a neurosurgical intervention, Deep Brain Sti...
- Phase 2A Study to Evaluate the Kappa Opioid Receptor as a Target for the Treatment of Mood and Anxiety Spectrum Disorders By Evaluating Whether LY2456302 Engages Reward-related Neural Circuitry
The purpose of this study is to investigate a drug (LY2456302) for the treatment of problems experiencing pleasure (anhedonia) in people with mood and anxiety disorders. The larger goal is to test whether we can establish Proof of Concept (POC) that kappa opioid receptor (KOR)...
- A Phase II, Multi-Center, Randomized, Double-Blind, Parallel-Group Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Combination with Selective Serotonin Reuptake Inhibitors in Patients with Obsessive Compulsive Disorder
Despite advances in the treatment of Obsessive Compulsive Disorder (OCD), most patients continue to experience disabling symptoms leading to impaired functioning and diminished quality of life. There remains a need to develop more effective and better tolerated long-term treat...
- Reclaim Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder
This is treatment rather than research. Medtronic Reclaim DBS Therapy for Obsessive-Compulsive Disorder (OCD) delivers electrical stimulation to areas in the brain to help control symptoms of OCD. Candidates for DBS Therapy have been diagnosed with chronic, severe, treatment-r...